Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection.
Unanticipated results from 2 recent candidate human immunodeficiency virus type 1 (HIV-1) vaccine regimens in large-scale international trials highlight the importance of understanding the optimal earliest immune defense against HIV-1 infection. Presented here are key findings in these vaccine studies with relevance to the development of future vaccines to control acute HIV-1 infection.
McElrath
M Juliana
MJ
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. jmcelrat@fhcrc.org
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans
D016915:AIDS Vaccines